Do analysts rate BIVI or ANVS?

Annovis Bio has a consensus target price of $12.00, suggesting a potential upside of 1,037.44%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts clearly believe Annovis Bio is more favorable than BioVie. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Annovis Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has stronger valuation and earnings, BIVI or ANVS?

Annovis Bio is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioVie N/A N/A -$22.07M -$3.15 N/A Annovis Bio N/A N/A -$28.85M -$1.79 N/A

Is BIVI or ANVS more profitable?

BioVie's return on equity of -126.02% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -126.02% -108.88% Annovis Bio N/A -685.98% -258.77%

Do analysts prefer BIVI or BKHA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, BIVI or BKHA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioVie N/A N/A -$22.07M -$3.15 N/A Black Hawk Acquisition N/A N/A N/A N/A N/A

Is BIVI or BKHA more profitable?

Black Hawk Acquisition's return on equity of 0.00% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -126.02% -108.88% Black Hawk Acquisition N/A N/A N/A

Does the media refer more to BIVI or BKHA?

In the previous week, Black Hawk Acquisition had 6 more articles in the media than BioVie. MarketBeat recorded 8 mentions for Black Hawk Acquisition and 2 mentions for BioVie. BioVie's average media sentiment score of 0.89 beat Black Hawk Acquisition's score of 0.27 indicating that BioVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioVie 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Black Hawk Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ELTX or BIVI?

Elicio Therapeutics currently has a consensus target price of $15.00, indicating a potential upside of 747.46%. Given Elicio Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Elicio Therapeutics is more favorable than BioVie. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elicio Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, ELTX or BIVI?

Elicio Therapeutics is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elicio Therapeutics N/A N/A -$39.57M -$2.17 N/A BioVie N/A N/A -$22.07M -$3.15 N/A

Is ELTX or BIVI more profitable?

BioVie's return on equity of -126.02% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Elicio Therapeutics N/A -1,266.43% -139.94% BioVie N/A -126.02% -108.88%

Do analysts recommend CELU or BIVI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CELU or BIVI more profitable?

BioVie has a net margin of 0.00% compared to Celularity's net margin of -374.87%. Celularity's return on equity of 0.00% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets Celularity -374.87% N/A -64.45% BioVie N/A -126.02% -108.88%

Do analysts rate BIVI or TIL?

Instil Bio has a consensus price target of $7.00, indicating a potential upside of 13.27%. Given Instil Bio's stronger consensus rating and higher probable upside, analysts clearly believe Instil Bio is more favorable than BioVie. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has preferable earnings & valuation, BIVI or TIL?

Instil Bio is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioVie N/A N/A -$22.07M -$3.15 N/A Instil Bio N/A N/A -$71.37M -$4.47 N/A

Is BIVI or TIL more profitable?

Instil Bio's return on equity of -26.78% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -126.02% -108.88% Instil Bio N/A -26.78% -14.89%

BioVie (BIVI) Competitors

$1.20 -0.12 (-9.09%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$1.23 +0.03 (+2.50%)

As of 07:53 AM Eastern

Compare

BIVI vs. ANVS, BKHA, ELTX, CELU, and TIL

Should you buy BioVie stock or one of its competitors? BioVie's main competitors and comparable companies include Annovis Bio (ANVS), Black Hawk Acquisition (BKHA), Elicio Therapeutics (ELTX), Celularity (CELU), and Instil Bio (TIL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioVie compare to Annovis Bio?

BioVie (NASDAQ:BIVI) and Annovis Bio (NYSE:ANVS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

BioVie has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

BioVie's return on equity of -126.02% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-126.02%	-108.88%
Annovis Bio	N/A	-685.98%	-258.77%

Annovis Bio has a consensus target price of $12.00, suggesting a potential upside of 1,037.44%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts clearly believe Annovis Bio is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Annovis Bio is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$22.07M	-$3.15	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A

4.6% of BioVie shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 16.7% of BioVie shares are held by insiders. Comparatively, 15.9% of Annovis Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, BioVie had 2 more articles in the media than Annovis Bio. MarketBeat recorded 2 mentions for BioVie and 0 mentions for Annovis Bio. BioVie's average media sentiment score of 0.89 beat Annovis Bio's score of 0.00 indicating that BioVie is being referred to more favorably in the media.

Company	Overall Sentiment
BioVie	Positive
Annovis Bio	Neutral

Summary

BioVie beats Annovis Bio on 7 of the 13 factors compared between the two stocks.

How does BioVie compare to Black Hawk Acquisition?

BioVie (NASDAQ:BIVI) and Black Hawk Acquisition (NASDAQ:BKHA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

In the previous week, Black Hawk Acquisition had 6 more articles in the media than BioVie. MarketBeat recorded 8 mentions for Black Hawk Acquisition and 2 mentions for BioVie. BioVie's average media sentiment score of 0.89 beat Black Hawk Acquisition's score of 0.27 indicating that BioVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioVie	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Black Hawk Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioVie has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, Black Hawk Acquisition has a beta of 0.02, suggesting that its stock price is 98% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$22.07M	-$3.15	N/A
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A

Black Hawk Acquisition's return on equity of 0.00% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-126.02%	-108.88%
Black Hawk Acquisition	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

4.6% of BioVie shares are held by institutional investors. 16.7% of BioVie shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

BioVie beats Black Hawk Acquisition on 4 of the 7 factors compared between the two stocks.

How does BioVie compare to Elicio Therapeutics?

Elicio Therapeutics (NASDAQ:ELTX) and BioVie (NASDAQ:BIVI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

In the previous week, BioVie had 1 more articles in the media than Elicio Therapeutics. MarketBeat recorded 2 mentions for BioVie and 1 mentions for Elicio Therapeutics. Elicio Therapeutics' average media sentiment score of 1.79 beat BioVie's score of 0.89 indicating that Elicio Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Elicio Therapeutics	Very Positive
BioVie	Positive

35.0% of Elicio Therapeutics shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 28.7% of Elicio Therapeutics shares are owned by company insiders. Comparatively, 16.7% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

BioVie's return on equity of -126.02% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-1,266.43%	-139.94%
BioVie	N/A	-126.02%	-108.88%

Elicio Therapeutics currently has a consensus target price of $15.00, indicating a potential upside of 747.46%. Given Elicio Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Elicio Therapeutics is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Elicio Therapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, BioVie has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market.

Elicio Therapeutics is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A
BioVie	N/A	N/A	-$22.07M	-$3.15	N/A

Summary

Elicio Therapeutics beats BioVie on 8 of the 12 factors compared between the two stocks.

How does BioVie compare to Celularity?

Celularity (NASDAQ:CELU) and BioVie (NASDAQ:BIVI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Celularity has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, BioVie has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

19.0% of Celularity shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 17.3% of Celularity shares are owned by insiders. Comparatively, 16.7% of BioVie shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Celularity and Celularity both had 2 articles in the media. Celularity's average media sentiment score of 0.93 beat BioVie's score of 0.89 indicating that Celularity is being referred to more favorably in the media.

Company	Overall Sentiment
Celularity	Positive
BioVie	Positive

BioVie has lower revenue, but higher earnings than Celularity. Celularity is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	1.74	-$91.72M	-$2.73	N/A
BioVie	N/A	N/A	-$22.07M	-$3.15	N/A

BioVie has a net margin of 0.00% compared to Celularity's net margin of -374.87%. Celularity's return on equity of 0.00% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-374.87%	N/A	-64.45%
BioVie	N/A	-126.02%	-108.88%

Summary

Celularity beats BioVie on 8 of the 11 factors compared between the two stocks.

How does BioVie compare to Instil Bio?

BioVie (NASDAQ:BIVI) and Instil Bio (NASDAQ:TIL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Instil Bio has a consensus price target of $7.00, indicating a potential upside of 13.27%. Given Instil Bio's stronger consensus rating and higher probable upside, analysts clearly believe Instil Bio is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

BioVie has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, Instil Bio has a beta of 1.94, indicating that its share price is 94% more volatile than the broader market.

In the previous week, BioVie had 1 more articles in the media than Instil Bio. MarketBeat recorded 2 mentions for BioVie and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.79 beat BioVie's score of 0.89 indicating that Instil Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
BioVie	Positive
Instil Bio	Very Positive

4.6% of BioVie shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 16.7% of BioVie shares are held by company insiders. Comparatively, 47.0% of Instil Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Instil Bio's return on equity of -26.78% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-126.02%	-108.88%
Instil Bio	N/A	-26.78%	-14.89%

Instil Bio is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$22.07M	-$3.15	N/A
Instil Bio	N/A	N/A	-$71.37M	-$4.47	N/A

Summary

Instil Bio beats BioVie on 8 of the 12 factors compared between the two stocks.

Get BioVie News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIVI vs. The Competition

Export

Metric	BioVie	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.46M	$3.93B	$7.27B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	-0.38	10.78	202.90	19.69
Price / Sales	N/A	1,146.43	561.48	81.34
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	0.88	16.70	10.61	6.03
Net Income	-$22.07M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-14.29%	-4.43%	-2.89%	-2.34%
1 Month Performance	-41.46%	-12.49%	-7.37%	-5.31%
1 Year Performance	-40.00%	7.63%	3.00%	-2.94%

BioVie Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIVI BioVie	1.4839 of 5 stars	$1.20 -9.1%	N/A	-38.5%	$11.46M	N/A	N/A	13	Analyst Upgrade
ANVS Annovis Bio	1.7555 of 5 stars	$1.22 +1.3%	$12.00 +887.7%	-35.5%	$51.86M	N/A	N/A	7
BKHA Black Hawk Acquisition	N/A	$12.47 +1.5%	N/A	+10.4%	$51.80M	N/A	N/A	2	News Coverage
ELTX Elicio Therapeutics	3.2492 of 5 stars	$1.92 flat	$15.00 +681.3%	-83.3%	$50.46M	N/A	N/A	N/A
CELU Celularity	0.6984 of 5 stars	$1.73 +0.9%	N/A	-30.4%	$49.94M	$26.55M	N/A	115	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIVI) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioVie (BIVI) Competitors